Verition Fund Management’s Protagonist Therapeutics PTGX Stock Holding History

Verition Fund Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.24M	Buy	+10,143	New	+$1.06M	0.01%	1343
2026 Q1	–	Sell	-26,792	Closed	-$2.34M	–	3286
2025 Q4	$2.34M	Buy	+26,792	New	+$2.19M	0.01%	1461
2025 Q2	–	Sell	-19,847	Closed	-$960K	–	3813
2025 Q1	$960K	Buy	+19,847	New	+$832K	﹤0.01%	2162
2024 Q3	–	Sell	-10,895	Closed	-$378K	–	3459
2024 Q2	$378K	Buy	10,895 +1,713	+19%	+$50.2K	﹤0.01%	2213
2024 Q1	$266K	Buy	+9,182	New	+$250K	﹤0.01%	2358
2023 Q3	–	Sell	-9,210	Closed	-$254K	–	2617
2023 Q2	$254K	Buy	+9,210	New	+$230K	﹤0.01%	1684

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Verition Fund Management's PTGX Position: Q2 2026 in Review

Verition Fund Management opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 10,143 shares worth $1.24M. The stake represents 0.01% of the portfolio and ranks #1343 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in PTGX as recently as Q4 2025.

Verition Fund Management first reported a position in PTGX in Q2 2023 and has held it in 6 quarters since. The position peaked at $2.34M in Q4 2025. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Verition Fund Management held 10,143 shares of Protagonist Therapeutics worth $1.24M as of Q2 2026.
Protagonist Therapeutics was a new Verition Fund Management position in Q2 2026.
Protagonist Therapeutics made up 0.01% of Verition Fund Management's portfolio in Q2 2026, its #1343 holding.
Verition Fund Management first reported a position in Protagonist Therapeutics in Q2 2023 and has held it in 6 quarters since.
Verition Fund Management's Protagonist Therapeutics position peaked at $2.34M in Q4 2025.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.